The Bioavailability of Mycoprotein

January 15, 2020 updated by: University of Exeter
To evaluate the bioavailability of mycoprotein, compared with a reference animal based protein, in a dose-response manner.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Devon
      • Exeter, Devon, United Kingdom, EX1 2LU
        • Sport & Health Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Healthy and aged 18-40 y
  • BMI between 18 and 30

Exclusion Criteria:

  • On medication
  • Family history of metabolic disease
  • Diagnosed with any metabolic or cardiovascular conditions
  • BMI < 18 or > 30

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Milk
Acute ingestion of 20 g milk protein
Other: Mycoprotein ingestion
EXPERIMENTAL: 20g
Acute ingestion of 20 g mycoprotein
Other: Mycoprotein ingestion
EXPERIMENTAL: 40g
Acute ingestion of 40 g mycoprotein
Other: Mycoprotein ingestion
EXPERIMENTAL: 60g
Acute ingestion of 60 g mycoprotein
Other: Mycoprotein ingestion
EXPERIMENTAL: 80g
Acute ingestion of 60 g mycoprotein
Other: Mycoprotein ingestion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Plasma total amino acid concentrations
Time Frame: 4 hours
4 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Exeter

Investigators

  • Principal Investigator: Benjamin T Wall, PhD, University of Exeter, College of Life and Environmental Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (ACTUAL)

August 1, 2017

Study Completion (ACTUAL)

January 1, 2018

Study Registration Dates

First Submitted

November 30, 2016

First Submitted That Met QC Criteria

January 15, 2020

First Posted (ACTUAL)

January 18, 2020

Study Record Updates

Last Update Posted (ACTUAL)

January 18, 2020

Last Update Submitted That Met QC Criteria

January 15, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 157758

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Availability of Mycoprotein

Clinical Trials on Mycoprotein ingestion

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe